The Environment in the Pathogenesis of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus: A Companion to Rheumatology

Volumn , Issue , 2007, Pages 64-73

  Sawalha, Amr H ^a,b   Richardson, Bruce C ^c  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 40349084364     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04434-9.50012-9     Document Type: Chapter

References (94)

1. Priori R, Medda E, Conti F, et al. Familial autoimmunity as a risk factor for systemic lupus erythematosus and vice versa: A case-control study. Lupus 2003, 12:735-740.
2. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992, 35:311-318.
3. Kelly JA, Moser KL, Harley JB The genetics of systemic lupus erythematosus: Putting the pieces together. Genes Immun 2002, 3:S71-S85.
4. Nath SK, Kilpatrick J, Harley JB Genetics of human systemic lupus erythematosus: The emerging picture. Curr Opin Immunol 2004, 4:800.
5. Yung RL, Richardson BC Drug-induced lupus 2003, 1385-1387. Elsevier Limited, New York. M.C. Hochberg, A.J. Silman, J.S. Smolen, M.E. Weinblatt, M.H. Weisman (Eds.).
6. Miller FW, Hess EV, Clauw DJ, et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000, 43:243-249.
7. Schoonen WM, Somers EC, Hall AJ Use of the General Practice Research Database to detect drug-induced autoimmune disease. Pharmacoepidemiol Drug Saf 2005, 14(S2):S199.
8. Yung RL, Richardson BC Drug-induced lupus. Rheum Dis Clin North Am 1994, 20:61-86.
9. Busslinger M, Hurst J, Flavell RA DNA methylation and the regulation of globin gene expression. Cell 1983, 34:197-206.
10. Clark SJ, Harrison J, Molloy PL Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 1997, 195:67-71.
11. Comb M, Goodman HM CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 1990, 18:3975-3982.
12. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19:187-191.
13. Attwood JT, Yung RL, Richardson BC DNA methylation and the regulation of gene transcription. Cell Mol Life Sci 2002, 59:241-257.
14. Deng C, Kaplan MJ, Yang J, et al. Decreased Ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.
15. MacLeod AR, Rouleau J, Szyf M. Regulation of DNA methylation by the Ras signaling pathway. J Biol Chem 1995, 270:11327-11337.
16. Santi DV, Normet A, Garrett CE Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984, 81:6993.
17. Richardson B. DNA methylation and autoimmune disease. Clinical Immunology 2003, 109:72-79.
18. van der Veen FM, Rolink AG, Gleichmann E. Autoimmune disease strongly resembling systemic lupus erythematosus (SLE) in F1 mice undergoing graft-versus-host reaction (GVHR). Adv Exp Med Biol 1982, 149:669-677.
19. Quddus J, Johnson KJ, Gavalchin J, et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest 1993, 92:38-53.
20. Sawalha AH, Richardson BC DNA methylation in the pathogenesis of systemic lupus erythematosus. Current Pharmacogenomics 2005, 3:73-78.
21. Lu Q, Kaplan M, Ray D, et al. Demethylation of ITGAL (CD11a) regulatory sequences in systemic lupus erythematosus. Arthritis Rheum 2002, 46:1282-1291.
22. Richardson B. Effect of an inhibitor of DNA methylation on T cells. II. 5-azacytidine induces self-reactivity in antigen-specific T4+ cells. Human Immunol 1986, 17:456.
23. Kaplan MJ, Beretta L, Yung RL, et al. LFA-1 overexpression and T cell autoreactivity: mechanisms. Immunol Invest 2000, 29:427-442.
24. Yung R, Powers D, Johnson K, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996, 97:2866-2871.
25. Lu Q, Wu A, Ray D, et al. DNA methylation and chromatin structure regulate T cell perforin gene expression. J Immunol 2003, 170:5124-5132.
26. Kaplan MJ, Lu Q, Wu A, et al. Demethylation of promoter regulatory elements contributes to perforin overexpression in CD4+ lupus T cells. J Immunol 2004, 172:3652-3661.
27. Mevorach D, Zhou JL, Song X, et al. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998, 188:387-392.
28. Walport MJ Lupus, DNase and defective disposal of cellular debris. Nat Genet 2000, 25:135-136.
29. Lu Q, Wu A, Richardson BC Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005, 174:6212-6219.
30. Oelke K, Lu Q, Richardson D, et al. Overexpression of CD70 and overstimulation of IgG synthesis by lupus T cells and T cells treated with DNA methylation inhibitors. Arthritis Rheum 2004, 50:1850-1860.
31. Fauci AS, Moutsopoulos HM Polyclonally triggered B cells in the peripheral blood and bone marrow of normal individuals and in patients with systemic lupus erythematosus and primary Sjogren's syndrome. Arthritis Rheum 1981, 24:577-583.
32. Young HA Regulation of interferon-gamma gene expression. J Interferon Cytokine Res 1996, 16:563-568.
33. Golbus J, Salata M, Greenwood J, et al. Increased immunoglobulin response to gamma-interferon by lymphocytes from patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1988, 46:129-140.
34. Perl A. Role of endogenous retroviruses in autoimmune diseases. Rheum Dis Clin North Am 2003, 29:123-143.
35. Tao Q, Robertson KD Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 2003, 109:53-63.
36. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004, 172:1287-1294.
37. Cornacchia E, Golbus J, Maybaum J, et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 1988, 140:2197-2200.
38. Yung R, Chang S, Hemati N, et al. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 1997, 40:1436-1443.
39. Scheinbart LS, Johnson MA, Gross LA, et al. Procainamide inhibits DNA methyltransferase in a human T cell line. J Rheumatol 1991, 18:530-534.
40. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracellular signal-regulated kinase pathway signaling. Arthritis Rheum 2003, 48:746-756.
41. Yung RL, Quddus J, Chrisp CE, et al. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 1995, 154:3025-3035.
42. Richardson B, Scheinbart L, Strahler J, et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 1990, 33:1665-1673.
43. Richardson BC, Strahler JR, Pivirotto TS, et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 1992, 35:647-662.
44. Lehmann P, Holzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990, 22:181-187.
45. Herzinger T, Plewig G, Rocken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004, 50:3045-3046.
46. Fruchter O, Edoute Y. First presentation of systemic lupus erythematosus following ultraviolet radiation exposure in an artificial tanning device. Rheumatology (Oxford) 2005, 44:558-559.
47. Haga HJ, Brun JG, Rekvig OP, et al. Seasonal variations in activity of systemic lupus erythematosus in a subarctic region. Lupus 1999, 8:269-273.
48. Golan DT, Borel Y. Increased photosensitivity to near-ultraviolet light in murine SLE. J Immunol 1984, 132:705-710.
49. Natali PG, Mottolese M, Nicotra M. Immune complex formation in NZB/W mice after ultraviolet radiation. Clin Immunol Immunopathol 1978, 10:414-419.
50. Ansel JC, Mountz J, Steinberg AD, et al. Effects of UV radiation on autoimmune strains of mice: increased mortality and accelerated autoimmunity in BXSB mice. J Invest Dermatol 1985, 85:181-186.
51. Lieberman MW, Beach LR, Palmiter RD Ultraviolet radiation-induced metallothionein-I gene activation is associated with extensive DNA demethylation. Cell 1983, 35:207-214.
52. Richardson B, Powers D, Hooper F, et al. Lymphocyte function-associated antigen 1 overexpression and T cell autoreactivity. Arthritis Rheum 1994, 37:1363-1372.
53. Li-Weber M, Treiber MK, Giaisi M, et al. Ultraviolet irradiation suppresses T cell activation via blocking TCR-mediated ERK and NF-KB signaling pathways. J Immunol 2005, 175:2132-2143.
54. Casiola-Rosen LA, Anhalt G, Rosen A. Autoantigen targets in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994, 179:1317-1330.
55. Furukawa F. Photosensitivity in cutaneous lupus erythematosus: Lessons from mice and men. J Dermatol Sci 2003, 33:81-89.
56. Frisoni L, McPhie L, Colonna L, et al. Nuclear autoantigen translocation and autoantibody opsonization lead to increased dendritic cell phagocytosis and presentation of nuclear antigens: A novel pathogenic pathway for autoimmunity?. J Immunol 2005, 175:2692-2701.
57. James JA, Kaufman KM, Farris AD, et al. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100:3019-3026.
58. James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44:1122-1126.
59. James JA, Scofield RH, Harley JB Lupus humoral autoimmunity after short peptide immunization. Ann N Y Acad Sci 1997, 815:124-127.
60. James JA, Gross T, Scofield RH, et al. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995, 181:453-461.
61. McClain MT, Heinlen LD, Dennis GJ, et al. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 2005, 11:85-89.
62. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000, 53:424-432.
63. Kang I, Quan T, Nolasco H, et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 2004, 172:1287-1294.
64. Tao Q, Robertson KD Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Clin Immunol 2003, 109:53-63.
65. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 1998, 41:1714-1724.
66. Sawalha AH, Schmid WR, Binder SR, et al. Association between systemic lupus erythematosus and Helicobacter pylori seroneg-ativity. J Rheumatol 2004, 31:1546-1550.
67. Hess EV Environmental chemicals and autoimmune disease: Cause and effect. Toxicology 2002, 181/182:65-70.
68. Sanchez-Roman J, Wichmann I, Salaberri J, et al. Multiple clinical and biological autoimmune manifestations in 50 workers after occupational exposure to silica. Ann Rheum Dis 1993, 52:534-538.
69. Conrad K, Melhorn J, Luthke K, Dorner T, Frank K-H Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: Clinical and serological characteristics. Lupus 1996, 5:62-69.
70. Linch KD, Miller WE, Althouse RB, et al. Surveillance of respirable crystalline silica dust using OSHA compliance data (1979-1995). Am J Ind Med 1998, 34:547-558.
71. Parks CG, Cooper GS, Nylander-French LA, et al. Occupational exposure to crystalline silica and risk of systemic lupus erythematosus: A population-based, case-control study in the southeastern United States. Arthritis Rheum 2002, 46:1840-1850.
72. Pernis B, Paronetto F. Adjuvent effects of silica (tridymite) on antibody production. Proc Soc Exp Biol Med 1996, 110:390-392.
73. Lim Y, Kim JH, Kim KA, et al. Silica-induced apoptosis in vitro and in vivo. Toxicol Lett 1999, 108:335-339.
74. Davis GS, Pfeiffer LM, Hemenway DR Persistent overexpression of interleukin-1beta and tumor necrosis factor-alpha in murine silicosis. J Environ Pathol Toxicol Oncol 1998, 17:99-114.
75. Clarkson TW, Magos L, Myers GJ The toxicology of mercury: Current exposures and clinical manifestations. N Engl J Med 2003, 349:1731-1737.
76. Cooper GS, Parks CG, Treadwell EL, et al. Occupational risk factors for the development of systemic lupus erythematosus. J Rheumatol 2004, 31:1928-1933.
77. Hultman P, Enestrom S. The induction of immune complex deposits in mice by peroral and parenteral administration of mercuric chloride: Strain dependent susceptibility. Clin Exp Immunol 1987, 67:283-292.
78. Hultman P, Enestrom S. Dose-response studies in murine mercury-induced autoimmunity and immune-complex disease. Toxicol Appl Pharmacol 1992, 113:199-208.
79. Pollard KM, Pearson DL, Hultman P, et al. Lupus-prone mice as models to study xenobiotic-induced acceleration of systemic autoimmunity. Environ Health Perspect 1999, 107(Suppl 5):729-735.
80. Pollard KM, Pearson DL, Hultman P, et al. Xenobiotic acceleration of idiopathic systemic autoimmunity in lupus-prone bxsb mice. Environ Health Perspect 2001, 109:27-33.
81. Hultman P, Bell LJ, Enestrom S, et al. Murine susceptibility to mercury. I. Autoantibody profiles and systemic immune deposits in inbred, congenic, and intra-H-2 recombinant strains. Clin Immunol Immunopathol 1992, 65:98-109.
82. Hultman P, Bell LJ, Enestrom S, et al. Murine susceptibility to mercury. II. autoantibody profiles and renal immune deposits in hybrid, backcross, and H-2d congenic mice. Clin Immunol Immunopathol 1993, 68:9-20.
83. Freni-Titulaer LW, Kelley DB, Grow AG, et al. Connective tissue disease in southeastern Georgia: A case-control study of etiologic factors. Am J Epidemiol 1989, 130:404-409.
84. Petri M, Allbritton J. Hair product use in systemic lupus erythematosus: A case-control study. Arthritis Rheum 1992, 35:625-629.
85. Sanchez-Guerrero J, Karlson EW, Colditz GA, et al. Hair dye use and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1996, 39:657-662.
86. Hardy CJ, Palmer BP, Muir KR, et al. Systemic lupus erythematosus (SLE) and hair treatment: A large community based case-control study. Lupus 1999, 8:541-544.
87. Jimenez-Alonso J, Sabio JM, Perez-Alvarez F, et al. Hair dye treatment use and clinical course in patients with systemic lupus erythematosus and cutaneous lupus. Lupus 2002, 11:430-434.
88. Sanchez-Guerrero J. Is cigarette smoking a risk factor for systemic lupus erythematosus? Comment on the article by Costenbader et al. Arthritis Rheum 2005, 52:1340-1341.
89. Bardana EJ, Malinow MR, Houghton DC, et al. Diet-induced systemic lupus erythematosus (SLE) in primates. Am J Kidney Dis 1982, 1:345-352.
90. Malinow MR, Bardana EJ, Pirofsky B, et al. Systemic lupus erythematosus-like syndrome in monkeys fed alfalfa sprouts: Role of a nonprotein amino acid. Science 1982, 216:415-417.
91. Roberts JL, Hayashi JA Exacerbation of SLE associated with alfalfa ingestion. N Engl J Med 1983, 308:1361.
92. Alcocer-Varela J, Iglesias A, Llorente L, et al. Effects of L-canavanine on T cells may explain the induction of systemic lupus erythematosus by alfalfa. Arthritis Rheum 1985, 28:52-57.
93. Morimoto I. A study on immunological effects of L-canavanine. Kobe J Med Sci 1989, 35:287-298.
94. Bengtsson AA, Rylander L, Hagmar L, et al. Risk factors for developing systemic lupus erythematosus: A case-control study in southern Sweden. Rheumatology (Oxford) 2002, 41:563-571.